NASDAQ:ARTV Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis $2.83 -0.17 (-5.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.82 -0.02 (-0.53%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Artiva Biotherapeutics Stock (NASDAQ:ARTV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Artiva Biotherapeutics alerts:Sign Up Key Stats Today's Range$2.74▼$2.9550-Day Range$1.47▼$3.6052-Week Range$1.47▼$17.31Volume86,600 shsAverage Volume261,563 shsMarket Capitalization$68.94 millionP/E RatioN/ADividend YieldN/APrice Target$17.80Consensus RatingBuy Company Overview Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California. Read More Artiva Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreARTV MarketRank™: Artiva Biotherapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 574th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArtiva Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtiva Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Artiva Biotherapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Artiva Biotherapeutics are expected to grow in the coming year, from ($4.95) to ($2.83) per share.Price to Book Value per Share RatioArtiva Biotherapeutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Artiva Biotherapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ARTV. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtiva Biotherapeutics does not currently pay a dividend.Dividend GrowthArtiva Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ARTV. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Artiva Biotherapeutics this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for ARTV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Artiva Biotherapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Artiva Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.40% of the stock of Artiva Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Artiva Biotherapeutics' insider trading history. Receive ARTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTV Stock News HeadlinesArtiva Biotherapeutics (ARTV) Projected to Post Quarterly Earnings on ThursdayJuly 31 at 3:41 AM | americanbankingnews.comArtiva Biotherapeutics Rings the Closing BellJuly 14, 2025 | nasdaq.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 2 at 2:00 AM | Brownstone Research (Ad)Will Artiva Biotherapeutics (NASDAQ:ARTV) Spend Its Cash Wisely?June 29, 2025 | finance.yahoo.comArtiva Biotherapeutics Approves Equity Plan AmendmentJune 25, 2025 | tipranks.comARTV - Artiva Biotherapeutics Inc Key Metrics - MorningstarJune 24, 2025 | morningstar.comMArtiva Biotherapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comLatest Artiva Biotherapeutics Stock News | NASDAQ:ARTV | BenzingaMay 22, 2025 | benzinga.comSee More Headlines ARTV Stock Analysis - Frequently Asked Questions How have ARTV shares performed this year? Artiva Biotherapeutics' stock was trading at $10.08 at the start of the year. Since then, ARTV shares have decreased by 71.9% and is now trading at $2.83. How were Artiva Biotherapeutics' earnings last quarter? Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced its earnings results on Thursday, May, 8th. The company reported ($0.83) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.15. When did Artiva Biotherapeutics IPO? Artiva Biotherapeutics (ARTV) raised $167 million in an initial public offering on Friday, July 19th 2024. The company issued 13,920,000 shares at a price of $12.00 per share. Who are Artiva Biotherapeutics' major shareholders? Artiva Biotherapeutics' top institutional shareholders include Y Intercept Hong Kong Ltd (0.13%) and Ground Swell Capital LLC (0.10%). Insiders that own company stock include Yong-Jun Huh and Global Strategic Fund I Venbio. View institutional ownership trends. How do I buy shares of Artiva Biotherapeutics? Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artiva Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI). Company Calendar Last Earnings5/08/2025Today8/02/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARTV Previous SymbolNASDAQ:ARTV CIK1817241 Webwww.artivabio.com Phone(858) 267-4467FaxN/AEmployees81Year FoundedN/APrice Target and Rating Average Price Target for Artiva Biotherapeutics$17.80 High Price Target$21.00 Low Price Target$12.00 Potential Upside/Downside+529.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.37 million Net MarginsN/A Pretax Margin-26,045.02% Return on Equity-75.95% Return on Assets-39.51% Debt Debt-to-Equity RatioN/A Current Ratio13.93 Quick Ratio13.93 Sales & Book Value Annual Sales$250 thousand Price / Sales275.76 Cash FlowN/A Price / Cash FlowN/A Book Value$7.68 per share Price / Book0.37Miscellaneous Outstanding Shares24,360,000Free Float19,149,000Market Cap$68.94 million OptionableN/A BetaN/A Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:ARTV) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.